



**Proteomics International**

LABORATORIES LTD

**ASX/Media Release**

**19 April 2018**

**ASX code: PIQ**

## **European PromarkerD patent granted for diabetic kidney disease covering 400 million people**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has been granted a patent for its pioneering diagnostic and predictive test for diabetic kidney disease, PromarkerD, in the major European countries of Britain, Germany, France, Italy, Spain and Turkey. The patent covers more than 400 million people across the six countries, or 5% of the global population.

The World Health Organisation estimates the European Region is home to 60 million diabetics, with 10.3% of men and 9.6% of women over 25 suffering from the condition. The prevalence of diabetes is increasing in the region, due mostly to increased weight, unhealthy diets and physical inactivity.

The breakthrough PromarkerD test was launched in Central America last month and Proteomics International continues to be engaged with potential partners to bring the test to market in mainland USA, Mexico, Japan, Australia, China and Europe.

The European patent number 3151012, titled “Biomarkers Associated with Diabetic Nephropathy”, came into effect on 21 March, 2018 and will extend until 20 September, 2031.

The European patent complements those already granted in the USA, Australia, Singapore, Russia, China and Japan. Patents remain pending in other major global jurisdictions for both diabetic and other forms of kidney disease.

ENDS

### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Paul Hart [Investor Relations]  
Director  
Canary Capital  
T: +61 421 051 474  
E: [phart@canarycapital.com.au](mailto:phart@canarycapital.com.au)

Susan Fitzpatrick-Napier [Media Contact]  
Digital Mantra Group  
T: +61 2 8218 2144  
E: [team@dmgpr.com](mailto:team@dmgpr.com)

### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

PILL (ASX: PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)